HC Wainwright Issues Optimistic Outlook for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for Arrowhead Pharmaceuticals in a research note issued to investors on Wednesday, January 21st. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will earn ($0.97) per share for the quarter, up from their previous forecast of ($1.05). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2026 earnings at ($1.26) EPS, FY2026 earnings at ($2.03) EPS, Q1 2027 earnings at ($0.99) EPS, Q2 2027 earnings at ($1.23) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($3.51) EPS.

Other analysts also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday. The Goldman Sachs Group boosted their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. Chardan Capital raised their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. B. Riley lifted their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Bank of America boosted their price objective on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $81.67.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $67.05 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $76.76. The company has a fifty day moving average of $62.41 and a 200-day moving average of $40.11. The stock has a market capitalization of $9.11 billion, a price-to-earnings ratio of -838.02 and a beta of 1.21.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC lifted its holdings in Arrowhead Pharmaceuticals by 2,923.0% in the fourth quarter. Farther Finance Advisors LLC now owns 11,941 shares of the biotechnology company’s stock worth $793,000 after buying an additional 11,546 shares during the period. Financial Enhancement Group LLC bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $373,000. State of Alaska Department of Revenue lifted its stake in shares of Arrowhead Pharmaceuticals by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 70,399 shares of the biotechnology company’s stock valued at $4,673,000 after purchasing an additional 831 shares during the period. Choreo LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $450,000. Finally, Ritholtz Wealth Management bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $262,000. 62.61% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, COO Patrick O’brien sold 49,493 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the transaction, the chief operating officer directly owned 474,908 shares in the company, valued at approximately $29,971,443.88. This represents a 9.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 16,250 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the sale, the director directly owned 115,240 shares of the company’s stock, valued at approximately $7,033,097.20. This represents a 12.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 510,836 shares of company stock worth $33,603,060 in the last ninety days. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised several near‑term and FY2026/FY2027 EPS estimates, reiterated a “Buy” rating and a $100 price target — the firm says improving forecasts and program progress support upside. HC Wainwright Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals
• Positive Sentiment: B. Riley bumped its price target to $101 (from $61) and kept a “Buy” stance, implying significant upside from recent levels and signaling continued analyst conviction after Arrowhead’s program updates. B. Riley Raises ARWR Price Target to $101
• Positive Sentiment: Piper Sandler highlighted Arrowhead’s pipeline ahead of Phase III hypertriglyceridemia data and has increased its target (reported lift to $110), underscoring the potential for a clinical readout to re‑rate the stock if data are positive. Piper Sandler Highlights Arrowhead Pipeline
• Neutral Sentiment: Broader coverage pieces (InsiderMonkey/TheFly) recap the analyst upgrades and pipeline milestones — useful for context but largely reiterative of the broker notes above. InsiderMonkey: Piper Sandler Highlights Arrowhead
• Negative Sentiment: Despite the upgrades, shares are down today amid lower‑than‑average volume — likely profit‑taking following the recent run and continued investor caution given persistent GAAP losses and upcoming binary clinical readouts (which carry upside but also clinical risk).

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.